Under Health Secretary Robert F. Kennedy Jr., the Food and Drug Administration (FDA) is reportedly considering a policy that would allow unproven peptide drugs to bypass rigorous testing, despite safety concerns raised by its own scientists. This policy, known as an “Interim Access Policy,” would grant the FDA “enforcement discretion” on certain peptides, enabling them to be made by specialty pharmacies without strict regulation.

The move comes as the FDA is re-evaluating twelve popular but scientifically unproven injectable peptides, which were previously removed from the compounding pharmacies’ list due to safety and efficacy concerns. Despite this, these peptides have gained popularity, with sellers claiming they can improve appearance, boost energy, and aid in injury recovery. Notably, many prominent figures from Kennedy’s Make America Healthy Again (MAHA) movement are involved in selling these products.

The proposal has raised eyebrows, with some fearing it could set a dangerous precedent for untested drugs. The Department of Health and Human Services did not respond to requests for comment, leaving the public in the dark. Critics argue that such a policy could undermine public trust in regulatory bodies and potentially harm public health.

For Kennedy, who is a vocal advocate for peptides, the policy aligns with his vision of ending what he has termed “FDA’s war” on these drugs. However, this move could also be seen as a political strategy to appeal to his movement’s base while ignoring scientific consensus.